Dr. Ed Park of Recharge Biomedical explains face blindness, or prosopagnosia, which affects about one in fifty people. A case of significant improvement after exosome treatment is presented. (n.b. Exosomes are not FDA-approved to treat face blindness)
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
